Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

PURPOSE: Immune-mediated adverse events (imAEs) may be associated with response to immune checkpoint inhibitors. We assessed the relationship between imAE development and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab (anti-programmed cell death ligand-1 [PD-L1])...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Agnish, Austin, Matthew, Kluger, Harriet M., Trunova, Nataliya, Mann, Helen, Shire, Norah, Morgan, Claire, Zhou, Diansong, Mugundu, Ganesh M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670978/
https://www.ncbi.nlm.nih.gov/pubmed/36405729
http://dx.doi.org/10.3389/fimmu.2022.1026964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670978/
https://www.ncbi.nlm.nih.gov/pubmed/36405729
http://dx.doi.org/10.3389/fimmu.2022.1026964

Ejemplares similares